Sonova (OTCMKTS:SONVY) Stock Rating Lowered by Jefferies Financial Group

Sonova (OTCMKTS:SONVY) was downgraded by equities researchers at Jefferies Financial Group from a “hold” rating to a “moderate sell” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other analysts have also issued research reports about the company. BNP Paribas Exane raised Sonova from a “strong sell” rating to a “strong-buy” rating in a report on Tuesday, March 10th. Royal Bank Of Canada raised Sonova to a “moderate buy” rating in a research report on Tuesday, November 18th. Finally, Zacks Research upgraded Sonova from a “strong sell” rating to a “hold” rating in a research note on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sonova presently has a consensus rating of “Moderate Buy”.

Sonova Price Performance

OTCMKTS:SONVY opened at $45.66 on Wednesday. Sonova has a one year low of $45.13 and a one year high of $68.76. The business has a fifty day moving average price of $52.20 and a 200-day moving average price of $53.36. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.91 and a current ratio of 1.24.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.